Wall Street Zen Downgrades Biodexa Pharmaceuticals (NASDAQ:BDRX) to Sell

Biodexa Pharmaceuticals (NASDAQ:BDRX) was downgraded by equities researchers at Wall Street Zen from a “hold” rating to a “sell” rating in a research note issued to investors on Saturday.

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Biodexa Pharmaceuticals in a report on Monday, December 29th. One analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, Biodexa Pharmaceuticals currently has an average rating of “Sell”.

Biodexa Pharmaceuticals Price Performance

Shares of NASDAQ BDRX opened at $0.83 on Friday. The stock has a 50 day moving average price of $1.57 and a 200 day moving average price of $4.25. Biodexa Pharmaceuticals has a 52 week low of $0.81 and a 52 week high of $26.50.

Institutional Investors Weigh In On Biodexa Pharmaceuticals

An institutional investor recently bought a new position in Biodexa Pharmaceuticals stock. Armistice Capital LLC acquired a new position in shares of Biodexa Pharmaceuticals PLC Unsponsored ADR (NASDAQ:BDRX) in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund acquired 100,000 shares of the company’s stock, valued at approximately $227,000. Armistice Capital LLC owned 14.71% of Biodexa Pharmaceuticals at the end of the most recent reporting period. Institutional investors and hedge funds own 17.51% of the company’s stock.

Biodexa Pharmaceuticals Company Profile

Biodexa Pharmaceuticals Plc, a clinical stage biopharmaceutical company, focuses on developing a pipeline of products for the treatment of Type 1 diabetes and rare/orphan cancers of the brain. Its lead product candidate Tolimidone, a selective activator of the lyn kinase enzyme, currently under Phase II studies for the treatment of Type 1 diabetes. The company is also developing MTX110, which is currently in Phase I studies for the treatment of diffuse intrinsic recurrent glioblastoma, diffuse midline glioma, and medulloblastoma; and MTD217, a program centered around a water-soluble drug formulation that can be easily infused or injected simultaneously, or sequentially, directly into the cancer microenvironment, currently under preclinical studies for the treatment of leptomeningeal disease.